Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.51 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 3/20 | 0.47 |
| ▸ | RBP4 | P02753 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20744463 | 1.00 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4GRIN2D | |
| SCHEMBL20744410 | 1.00 | CHRNB4 (0.52) | CHRNB4CHRNA3CHRNB2CHRNA4GRIN2D | |
| SCHEMBL20744518 | 0.92 | GRIN2D (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4GRIN2D | |
| SCHEMBL30876487 | 0.84 | SLC2A1 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL30876501 | 0.84 | SLC2A1 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL22406147 | 0.84 | SLC2A1 (0.53) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL20744411 | 0.84 | TEAD1 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL20744503 | 0.84 | TEAD1 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL20744395 | 0.84 | TEAD1 (0.43) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19610437 | 0.84 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668877-B1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2024-05-01 | — | — | EP | disclosed |
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2021-04-20 | — | — | US | disclosed |
| US-20200289463-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2020-09-17 | — | — | US | disclosed |
| EP-3668877-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | Istituto Europeo di Oncologia S.r.l. (IT) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019034774-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | ISTITUTO EUROPEO DI ONCOLOGIA (IEO) S.R.L. (IT) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10980777-B2 | Indole derivatives as histone demethylase inhibitors | KDM1B, KDM1A, INMT | CHRNB4 1472/4885CHRNA3 699/4885CHRNB2 954/4885 |
| US-20200289463-A1 | INDOLE DERIVATIVES AS HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, INMT | CHRNB4 1472/4885CHRNA3 699/4885CHRNB2 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.